Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum
- Pivotal phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at ECTRIMS congress 2019
- 74% reduction in the risk of relapse for satralizumab monotherapy versus placebo in people with neuromyelitis optica spectrum disorder (NMOSD) with aquaporin-4 antibodies (AQP4-IgG seropositive patients)
- Satralizumab demonstrated a similar safety profile compared to placebo in two phase III studies across a broad population
Satralizumab targets the interleukin-6 (IL-6) receptor, a key driver of NMOSD
Basel, 12 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) presented today full pivotal phase III study results for satralizumab as a monotherapy for neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating central nervous system disease. Results from the SAkuraStar study, presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), show that satralizumab monotherapy achieved a 55% reduction in the risk of relapses compared to placebo in the overall population, representative of NMOSD patients (HR 0.45, 95% CI: 0.23-0.89; p=0.0184). In the large (~67%) subgroup of patients seropositive for AQP4-IgG antibodies, the effect was higher with a 74% reduction in risk of relapses (HR 0.26, 95% CI: 0.11-0.63; p=0.0014). People who are AQP4-IgG seropositive tend to experience a more severe disease course.
“The positive phase III results for satralizumab, first as an add-on therapy and now as a monotherapy are exciting to see, and importantly, it achieved efficacy in a broad range of NMOSD patients, reflective of what we see in our everyday practice. Satralizumab targets the IL-6 receptor, potentially offering a novel treatment approach,” said Professor Jeffrey Bennett, University of Colorado Neurology & Ophthalmology. “Approved treatment options demonstrating favourable safety and efficacy in controlled clinical trials are urgently needed. Even one relapse may lead to blindness and debilitating motor dysfunction for people with NMOSD.”
In the overall satralizumab-treated population, 76.1% were relapse-free at 48 weeks, and 72.1% relapse-free at 96 weeks, compared to 61.9% and 51.2% with placebo, respectively. Data from the AQP4-IgG seropositive subgroup showed that 82.9% were relapse-free at 48 weeks and 76.5% relapse-free at 96 weeks when treated with satralizumab, compared to 55.4% and 41.1% with placebo, respectively.
NMOSD is commonly associated with pathogenic antibodies (AQP4-IgG) that target and damage a specific cell type, called astrocytes, resulting in inflammatory lesions of the optic nerve(s), spinal cord and brain. Through the use of a diagnostic biomarker test, most NMOSD patients are identified as AQP4-IgG seropositive; however, as many as one-third of patients with NMOSD are AQP4-IgG seronegative. The condition is often misdiagnosed as multiple sclerosis.
Satralizumab inhibits IL-6 signalling, which is believed to play a key role in the inflammation that occurs in people with NMOSD, leading to damage and disability. People with NMOSD experience unpredictable, severe relapses that directly cause cumulative, permanent neurological damage.
“While first described 125 years ago, the underlying biology of NMOSD has only recently been understood. The positive results from the pivotal SAkuraStar and SAkuraSky studies support the hypothesis that IL-6 plays a key role in this devastating disease that can take away people’s independence,” said Sandra Horning, MD, Roche’s Chief Medical Officer and Head of Global Product Development. “We are encouraged by these results and look forward to working with regulators over the coming months to bring satralizumab to people living with NMOSD as soon as possible.”
These SAkuraStar data add to the previously reported results for satralizumab in combination with baseline therapy for people with NMOSD. Initial phase III data for SAkuraSky were presented at the 34th ECTRIMS congress in 2018. The data showed a 62% reduction in the risk of relapses in a representative population of both AQP4-IgG seropositive and AQP4-IgG seronegative patients in the overall study population (HR 0.38, 95% CI: 0.16-0.88; p=0.0184) when used in combination with baseline therapy compared to placebo, and a 79% reduction in the risk of relapses in AQP4-IgG seropositive patients (HR 0.21, 95% CI: 0.06-0.75; p=0.0086).
Overall, the proportion of patients with serious adverse events was similar between the satralizumab monotherapy and placebo treatment groups in the SAkuraStar study; and between the satralizumab added to baseline therapy and placebo added to baseline therapy treatment groups in the SAkuraSky study. A lower rate of infections (including serious infections) was observed in patients treated with satralizumab compared with the placebo group. In both studies, most adverse events were mild to moderate, and the most common adverse events in the satralizumab group were urinary tract infections and upper respiratory tract infections in the SAkuraStar study and upper respiratory tract infections, nasopharyngitis (common cold) and headache in the SAkuraSky study. Safety analyses continue in the open-label extensions of SAkuraStar and SAkuraSky.
The data available across two controlled, randomised phase III clinical trials suggest that satralizumab could be an efficacious option for patients across a broad NMOSD patient population, whether given as a monotherapy or in combination with baseline therapy. Satralizumab is administered every four weeks by subcutaneous injection, which may be a convenient option for patients and carers.
The SAkuraStar study recruited 95 NMOSD patients from the age of 20-70 and SAkuraSky recruited 83 patients, including adolescents, aged 13-73. These studies represent one of the largest clinical trial programmes undertaken for this rare disease.
About SAkuraStar and SAkuraSky in NMOSD
SAkuraStar is a phase III multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of satralizumab monotherapy administered to patients with NMOSD. The primary endpoint is the time to first protocol-defined relapse (PDR), adjudicated by an independent review committee in the double-blind period. Secondary endpoints included the Visual Analogue Scale (VAS) score for pain and Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue score.
Ninety-five patients aged from 20-70 years were randomised to either of the following two treatment groups in a 2:1 ratio: satralizumab (120 mg) or placebo. Both treatments were administered subcutaneously at Week 0, 2, and 4. The subsequent treatment was continued at 4-week intervals. The double-blind treatment period ended when the total number of PDRs had reached 44 or at 1.5 years after the enrollment of the last patient, whichever occurred first. After experiencing a PDR or upon completion of the study, patients in both groups were offered treatment with satralizumab in an open-label extension period. Patients with AQP4-IgG seropositive or seronegative neuromyelitis optica (NMO, as defined by the diagnostic criteria in 2006) and those with AQP4-IgG seropositive NMOSD were enrolled.
SAkuraSky is a phase III multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of satralizumab added to baseline immunosuppressant therapy in patients with NMOSD. The primary endpoint was the time to first relapse as adjudicated by an independent review committee in the double-blind period. Main secondary endpoints included change in VAS score for pain and change in FACIT Fatigue score.
Eighty-three male and female patients aged from 13 to 73 years were randomised to either of the following two treatment groups in a 1:1 ratio: satralizumab (120 mg) or placebo added to baseline therapy (azathioprine, mycophenolate mofetil and/or corticosteroids). Both treatments were administered subcutaneously at Week 0, 2, and 4. The subsequent treatment was continued at 4-week intervals. The double-blind treatment ended when patients experienced a PDR; the study ended when the total number of PDRs reached 26. After experiencing a PDR or upon completion of the study, patients in both groups were offered treatment with satralizumab in an open-label extension period. Patients with AQP4-IgG seropositive or seronegative neuromyelitis optica (NMO, as defined by diagnostic criteria in 2006) and those with AQP4-IgG seropositive NMOSD were enrolled.
About neuromyelitis optica spectrum disorder (NMOSD)
NMOSD is a rare, lifelong and debilitating autoimmune disease of the central nervous system that primarily damages the optic nerve(s) and spinal cord, causing blindness, muscle weakness and paralysis. People with NMOSD experience unpredictable, severe relapses directly causing cumulative, permanent, neurological damage and disability. In some cases, relapse can result in death. NMOSD affects over 10,000 people in Europe, 15,000 people in the US and up to hundreds of thousands of people worldwide. The disease is most common among non-Caucasian women in their 30s and 40s.
NMOSD is commonly associated with pathogenic antibodies (AQP4-IgG) that target and damage a specific cell type, called astrocytes resulting in inflammatory lesions of the optic nerve(s), spinal cord and brain. AQP4-IgG antibodies are detectable in the blood serum of around two-thirds of NMOSD patients.
Although most cases of NMOSD can be confirmed through a diagnostic test, people living with the condition are still frequently misdiagnosed with multiple sclerosis. This is due to overlapping features of the two disorders, including a higher prevalence in women, similar symptoms and the fact that both are relapse-based conditions.
Satralizumab is an investigational humanised monoclonal antibody that targets the IL-6 receptor. The cytokine IL-6 is thought to be a key driver in NMOSD, triggering the inflammation cascade and leading to damage and disability. Positive phase III results for satralizumab, as both monotherapy and in combination with baseline therapy, suggest that IL-6 inhibition may be an effective therapeutic approach for NMOSD. The phase III clinical development programme for satralizumab includes two studies: SAkuraStar and SAkuraSky.
About Roche in neuroscience
Neuroscience is a major focus of research and development at Roche. The company’s goal is to develop treatment options based on the biology of the nervous system to help improve the lives of people with chronic and potentially devastating diseases.
Roche has more than a dozen investigational medicines in clinical development for diseases that include multiple sclerosis, Alzheimer’s disease, Huntington’s disease, spinal muscular atrophy, Parkinson’s disease and autism.
|Living with NMOSD: Advice from a working mother||Learning about the science behind NMOSD|
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the tenth consecutive year, Roche has been recognised as the most sustainable company in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2018 employed about 94,000 people worldwide. In 2018, Roche invested CHF 11 billion in R&D and posted sales of CHF 56.8 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: firstname.lastname@example.org
- Nicolas Dunant (Head)
- Patrick Barth
- Ulrike Engels-Lange
- Daniel Grotzky
- Karsten Kleine
- Nathalie Meetz
- Barbara von Schnurbein
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire
Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire
Conversion factor for Exchange offer in SGB IL 3102 2019-09-2020.9.2019 11:04:00 CEST | Press release
2019-09-20 Conversion factor SGB IL 3102/3112; 4.7652335 The conversion factor of SGB IL 3102/3112 indicates the amount of SGB IL 3102 that the SNDO will buy back for each SGB IL 3112 issued in the switch auction at September 20, 2019. For further information, please contact: The funding desk + 46 8 613 4780 Funding@riksgalden.se
Buy-back yield SGB IL 3102 2019-09-2020.9.2019 10:45:00 CEST | Press release
2019-09-20 Buy-back yield SGB IL 3102; -2.1100% The buy-back yield of SGB IL 3102 is the yield at which the SNDO will buy SGB IL 3102in the switch auction vs SGB IL 3112 on September 20, 2017. For more information, please contact: The funding desk + 46 8 613 4780 FO@riksgalden.se
Jays Headphones announce partnership with Princeton Ltd in Japan20.9.2019 10:30:00 CEST | Press release
General press release Swedish lifestyle and audio product developer Jays Headphones announce a new partnership for distribution in Japan, one of the biggest heaphone markets. Starting September Princeton Technology Ltd, one of the leading distributors of consumer electronics and accessories in Jap an, will start distributing Jays Headphones. Northbaze Group (publ) announces a new partnership for distribution of Jays headphones in Japan, starting Q3 2019. The agreement involves Jays current and future product range including their latest launch, m-Seven True Wireless. Princeton Techonlogy Ltd was founded in 1995 and has a strong position on the the Japanese Consumer Electronic market. Princeton offers a wide variety of digital gadgets and accessories for tablets and smartphones and supply all major retail and e-tail channels in Japan. “I’m very excited about this partnership. Japan is a huge headphone market with a lot of potential. With Princeton I am confident that we have found the r
Jays Headphones inleder samarbete med Princeton Ltd i Japan20.9.2019 10:30:00 CEST | Pressemelding
Generellt pressmeddelande Svenska livsstilsvarumärket och hörlurstillverkaren Jays inleder nytt samarbete för distribution i Japan, en av världens största marknader för hörlurar. Från och med september kommer Princeton Techonlogy Ltd att distribuera Jays produkter i Japan. Princeton är av de ledande distributörerna i konsumentelektronik på den japanska marknaden. Northbaze Group ägda Jays Headphones tillkännager ett nytt partnerskap för distribution och försäljning av Jays i Japan, med start i Q3 2019. Avtalet innefattar Jays nuvarande och kommande sortiment inklusive den nyligen lanserade ”m-Seven True Wireless”. Princeton Technology Ltd som grundades 1995 har en lång erfarenhet från japanska konsumentelektronikmarknaden. Sortimentet består i huvudsak av tillbehör till smartphones och surfplattor. Man levererar och har nära relationer med samtliga ledande detalj- och e-handels butiker i Japan. ”Jag har stora förväntningar på detta samarbetet. Japan är efter USA världens andra största
Better Collective invests in Mindway AI; artificial intelligence technology for safer gambling20.9.2019 08:45:00 CEST | Press release
Regulatory release 29/2019 Better Collective has acquired 19,99% of the shares in Mindway AI, who specialises in innovative and advanced software solutions for the identification of at-risk gambling and problem gambling behaviour. The investment aligns Better Collective’s vision to empower iGamers and help establishing an entertaining and safe betting environment. The world’s leading developer of digital platforms for bookmaker information, tipster communities, and betting tips, Better Collective, has acquired 19,99% of the Danish software company, Mindway AI A/S, for a total price of 4 million DKK. Better Collective will under certain performance-based conditions acquire the remaining shares at a price of 20 million DKK. Furthermore, Better Collective has provided a loan of 4 million DKK to the company. Provider of early detection and intervention solutions for safer gambling Mindway AI is an award-winning company that specialises in software solutions that can identify at-risk gambli
Ålandsbanken, ICA Banken, Ikano Bank, Söderberg & Partners och Borgo startar hypoteksbolag tillsammans20.9.2019 08:00:00 CEST | Pressemelding
Ålandsbanken Abp Börsmeddelande 20.9.2019 kl. 9.00 Ålandsbanken, ICA Banken, Ikano Bank, Söderberg & Partners och Borgo startar hypoteksbolag tillsammans Ålandsbanken, ICA Banken, Ikano Bank, Söderberg & Partners och Borgo har tecknat avtal angående att etablera ett gemensamt hypoteksbolag på den svenska marknaden. - Att lansera ett nytt hypoteksbolag tillsammans med så starka och etablerade partners som ICA Banken, Söderberg & Partners och Ikano Bank säkerställer långsiktighet och stabilitet och ger bra förutsättningar att erbjuda bolån till bra villkor. Detta gynnar oss och våra samarbetspartners men naturligtvis även svenska bolånekunder i slutändan, säger Peter Wiklöf, vd på Ålandsbanken. Ålandsbanken och deras dotterbolag Crosskey kommer att tillhandahålla plattformslösningar för det nya hypoteksbolaget liksom bidra med befintlig kunskap om bolånehantering. - Genom att etablera ett nytt hypoteksbolag kan vi konkurrera på bolånemarknaden på ett helt nytt sätt och flytta fram våra p